Pictura Bio Raises $9.1M Series A for One-Minute Infectious Disease Diagnostics

Pictura Bio Secures $9.1M Series A

Pictura Bio, a University of Oxford spin-out founded in 2022 and formerly known as OxDX, has raised a $9.1 million Series A round. The financing supports the company's push to commercialize a diagnostics platform designed to identify infectious pathogens and their strains directly in clinical samples in about one minute.

What the Company Does

Pictura Bio is building one-minute infectious-disease diagnostics. Its platform combines two core elements:

• PIC-ID, a universal fluorescent labelling reagent
• VISTA, a benchtop fluorescence reader

The system pairs this hardware with deep-learning image analysis to identify pathogens and their strains directly in clinical samples. Rather than relying on pathogen-specific test panels, Pictura's approach uses a single reagent with software-updatable detection — meaning the platform's capabilities can be extended through software rather than requiring new, pathogen-specific hardware or chemistry for each target.

That architecture is the company's central differentiator: a single reagent and an updatable detection layer, positioned as a replacement for the fixed panels that dominate many current diagnostic workflows.

Clinical and Defense Validation

Pictura Bio is not purely a laboratory-stage concept. The company is running the ResVir respiratory clinical study with NHS Portsmouth's Queen Alexandra Hospital, a real-world clinical setting for its respiratory diagnostics work.

Separately, the company delivered a ruggedized prototype under a contract with the UK Ministry of Defence's DASA (Defence and Security Accelerator). That work points to use cases beyond standard clinical labs, where portability and durability matter.

Existing Backing

Pictura Bio is backed by IQ Capital, Ahren Innovation Capital, and Science Creates Ventures. These investors were already associated with the company prior to this Series A announcement.

Why It Matters for the Diagnostics Landscape

The infectious-disease diagnostics market has long been organized around pathogen-specific tests. Each new target typically requires its own assay, reagents, and validation path. Pictura's proposition — a universal labelling reagent combined with imaging and deep learning — aims to collapse that complexity into a single, updatable platform.

If the approach holds up in clinical use, the implications for acquisition interest are straightforward. Diagnostics incumbents and life-science tools companies have consistently pursued platforms that can expand their menu without rebuilding their installed base. A software-updatable detection layer is, in effect, a menu-expansion mechanism.

Key Facts at a Glance

• Company: Pictura Bio (formerly OxDX)
• Origin: University of Oxford spin-out
• Founded: 2022
• Round: Series A
• Amount: $9.1 million
• Announced: September 28, 2026
• Platform: PIC-ID universal fluorescent labelling reagent + VISTA benchtop fluorescence reader + deep-learning image analysis
• Clinical study: ResVir respiratory clinical study with NHS Portsmouth's Queen Alexandra Hospital
• Defense work: Ruggedized prototype delivered under a UK Ministry of Defence DASA contract
• Investors: IQ Capital, Ahren Innovation Capital, Science Creates Ventures

What to Watch

The Series A gives Pictura Bio capital to advance a platform that sits at the intersection of reagents, hardware, and machine learning. For acquirers in diagnostics and life-science tools, the company's combination of a clinical study, a defense-validated prototype, and an updatable detection architecture makes it a name worth tracking as it moves toward broader commercial deployment.